Aastrom Biosciences Inc  

(Public, NASDAQ:VCEL)   Watch this stock  
Find more results for NASDAQ:ASTM
2.84
+0.06 (2.34%)
Nov 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.72 - 2.84
52 week 2.55 - 7.00
Open 2.78
Vol / Avg. 18,221.00/108,640.00
Mkt cap 66.71M
P/E     -
Div/yield     -
EPS -3.99
Shares 23.79M
Beta 1.12
Inst. own 46%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -71.62% -82221.05%
Operating margin -83.06% -110336.80%
EBITD margin - -107763.20%
Return on average assets -79.02% -128.09%
Return on average equity - -
Employees 40 -
CDP Score - -

Address

24 FRANKL LLOYD WRIGHT DR, PO Box 376
ANN ARBOR, MI 48106
United States - Map
+1-734-9305555 (Phone)
+1-734-6650485 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage specialty biologics company with a portfolio of marketed and late-stage cell therapy products. The Company is engaged in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The Company markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant product for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), an autologous permanent skin replacement for the treatment of severe burns. It is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Officers and directors

Robert L. Zerbe M.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Dominick C Colangelo President, Chief Executive Officer, Chief Accounting Officer, Treasurer, Director
Age: 50
Bio & Compensation  - Reuters
Gerard J. Michel Chief Financial Officer, Vice President - Corporate Development
Age: 51
Bio & Compensation  - Reuters
Daniel R. Orlando Chief Operating Officer, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Ross Tubo Chief Scientific Officer
Bio & Compensation  - Reuters
David Recker Chief Medical Officer
Bio & Compensation  - Reuters
Heidi Hagen Director
Age: 45
Bio & Compensation  - Reuters
Timothy M. Mayleben Director
Age: 53
Bio & Compensation  - Reuters
Alan L. Rubino Independent Director
Age: 59
Bio & Compensation  - Reuters
Nelson M. Sims Independent Director
Age: 66
Bio & Compensation  - Reuters